3 Tips on Valuations and Exits for Emerging Healthcare Companies
Last week, I sat on a panel session at the IMPACT 2011 Venture Summit Mid-Atlantic conference held by the Greater Philadelphia Alliance for Capital and Technologies (PACT)…
Posted by
Last week, I sat on a panel session at the IMPACT 2011 Venture Summit Mid-Atlantic conference held by the Greater Philadelphia Alliance for Capital and Technologies (PACT)…
Posted by
Contrary to popular belief, a startup’s success does not solely hinge on the idea, but the leadership and talent that drive the company forward. For…
Posted by
Here at Safeguard Scientifics, we provide capital to growth-stage companies in both the life sciences and technology. It’s important to note, however, that Safeguard provides…
Posted by
We are constantly being reminded of the economic challenges impacting members of the European Union. It is no surprise that the economic upheaval in Greece…
Posted by
Safeguard Scientifics has a unique and consistent approach to putting capital to work in the life sciences sector. We target capital efficient diagnostic companies that…
Posted by
The convergence between life sciences and technology cannot be ignored. That’s why at Safeguard Scientifics, we consolidated of our life sciences and technology deal teams.…
Posted by
According to a report published by Cambridge Associates LLC, private equity and venture capital funds in the U.S. continued to generate positive returns for their…
Posted by
The IPO Task Force unveiled a new effort to ease the IPO road for emerging companies in its report, “Rebuilding the IPO On-Ramp.” The report…
Posted by
Safeguard Scientifics announced today that it has signed a definitive agreement to acquire a 36% ownership interest in Penn Mezzanine, a mezzanine platform which commenced operations…
Posted by